According
to the latest report published by Credence Research, Inc. “Human Chorionic Gonadotropin Market (Treatments:
Female Infertility, Oligospermia, Cryptorchidism & Others; Technology:
Natural Source Extraction & Recombinant DNA Technology): Growth, Future
Prospects and Competitive Analysis, 2016-2022,” the human chorionic
gonadotropin market was valued at USD346.3 MN in 2015, and is expected to reach
USD533.7Mn by 2022, expanding at a CAGR of 6% from 2016 to 2022.
Browse
the full report Human Chorionic Gonadotropin Market @ http://www.credenceresearch.com/report/human-chorionic-gonadotropin-market
Market
Insights
Infertility
treatment in both males and females is the major treatment area where HCG is
commonly administered. Growing incidence of infertility in women, contributed
by increased maternity age, lifestyle effects and others, hormonaldys functions
in men and growing incidence of oligospermia are the key factors that have
supported the demand for HCG drugs in the market. The demand for HCG is steady
in developed markets of Europe and North America. On the other hand, growing
awareness in general population and development of healthcare infrastructure
are supporting the growth in demand for HCG drugs in emerging markets.
Request
for Customization: http://www.credenceresearch.com/request-for-customization/57982
HCG supports the normal
development of egg in ovary and stimulates egg release during ovulation. It is
also used for infertility treatment in women and to augment sperm count in men.
Young boys with undescended testicles are also administered HCG treatment. Hugh
prevalence of both male and female infertility issues, expanding incidence of
low sperm count and sperm density in men are is the key factor driving the HCG
drugs market. A majority of the products currently available in the market are
natural source, i.e. urine derived HCG. However, in view of batch to batch
inconsistency in product purity and requirement of large amount of urine has
resulted in emergence of recombinant production technology.
North
America is expected to be the largest and most potential regional market for
human chorionic gonadotropin. North America constitutes regional markets of
U.S.and Canada, the rising incidence of infertility cases, lifestyle effects
and others, hormonal dysfunctions in men and women are the major driver for the
growth of the global human chorionic gonadotropin market. Asia-Pacific is the
expected to be the most potential regional market for human chorionic
gonadotropin market by2022. Over the next six years, the growth of the market
in the Asia-Pacific region is likely to be centered in Japan, South Korea,
China, and India. The key players in human chorionic gonadotropin market are
EMD Serono, Inc.,Ferring B.V., Merck & Co., Inc., Bristol Myers Squibb
Company and Fresenius KabiUSA, LLC.
About Us:
Credence Research is a
worldwide market research and counseling firm that serves driving
organizations, governments, non-legislative associations, and not-for-benefits.
We offer our customers some assistance with making enduring enhancements to
their execution and understand their most imperative objectives. Over almost a
century, we’ve manufactured a firm extraordinarily prepared to this task.
Media Contact
Name: Chris Smith (Global Sales Manager)
Address: 105 N 1st ST #429, SAN JOSE, CA 95103 US
E-mail: sales@credenceresearch.com
Ph: 1-800-361-8290
No comments:
Post a Comment